-
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Early Access Pathways in Italy and France: Law 64896 vs. the French AAP
Sep 9, 2025, 16:22 PM -
The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways
Sep 9, 2025, 16:22 PM -
Evolving Payer Preferences for Health Economic Information and Communication in the US
Sep 9, 2025, 16:22 PM -
Reducing Premature Cancer Mortality Through Early Stage Treatment: A Markov Model Analysis of Pembrolizumab Across Four Tumor Types
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life (HRQoL) and Its Associated Factors among Chinese Gout Patients: Baseline Findings From a Survey Study
Sep 9, 2025, 16:22 PM -
Changes in Medical Technology Availability in Europe Between 2000 and 2020
Sep 9, 2025, 16:22 PM -
Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study
Sep 9, 2025, 16:22 PM -
High Entry Costs Slower Growth: A Nationwide Register Study on Newly Reimbursed Biologic Medicines in Finland 2011-2021
Sep 9, 2025, 16:22 PM -
Modeling the Environmental and Cost Impact of a Novel Detergent in NHS Endoscope Reprocessing Workflows
Sep 9, 2025, 16:22 PM -
Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis
Sep 9, 2025, 16:22 PM -
Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood
Sep 9, 2025, 16:22 PM -
Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2024
Sep 9, 2025, 16:22 PM -
Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Evolution of MRD in Hemato-Oncology Clinical Development
Sep 9, 2025, 16:22 PM -
Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel
Sep 9, 2025, 16:22 PM -
Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom
Sep 9, 2025, 16:22 PM -
Economic and Social Burden of Pulmonary Hypertension in Italy
Sep 9, 2025, 16:22 PM -
Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma
Sep 9, 2025, 16:22 PM -
How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions
Sep 9, 2025, 16:22 PM
